Hims & Hers continues expanding internationally and strengthening its core healthcare platform beyond longevity therapies.
One prioritizes rapid consumer growth and profitability; the other commands scale but faces concentration risk.
Zacks Investment Research on MSN
Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $36.17, marking a -5.51% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.45%.
Key Points Interested in Hims & Hers Health, Inc.? Here are five stocks we like better. Employers are expected to drop ...
Hims & Hers Health has delivered a very large 3 year return, yet the stock still screens as undervalued on market multiples ...
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced Hims & Hers Benefits, a new way for subscribers to access the best ...
From connected fitness and cycle tracking to meal delivery and glucose monitoring, Hims & Hers subscribers now have ten ways to support their whole-body health Hims & Hers Health, Inc. (NYSE: HIMS), ...
(Corrects paragraph 15 to reflect that Hims & Hers is one of the most volume-producing of Novo’s partners, and not the most ...
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...
The company is profitable, and its subscriber base is growing. Hims & Hers makes and sells drugs. That's not remotely unusual. The key difference is the way the company interacts with its customers, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results